



RECEIVED

DEC 30 2002

CP/1635

Attorney's Docket No. 5218.87

TECH CENTER 1600/2900 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Phibbs, et al.
Serial No.: 09/747,514
Filed: December 21, 2000
For: CATABOLITE REPRESSION CONTROL (crc) GENE AND
PSUEDOMONAS VIRULENCE

Group Art Unit: 1635

Examiner: T. Gibbs

#10/K.T.
1/2/03
A

December 18, 2002

Commissioner for Patents
Washington, DC 20231

AMENDMENT

Sir:

This Amendment is responsive to the Office Action mailed July 18, 2002. It is respectfully requested that this application be reconsidered in view of the amendments and remarks set forth below. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The marked-up version of the changes is captioned "Version With Markings To Show Changes Made."

In the Specification:

Please replace the paragraph starting on page 17, lines 3-13, with the following replacement paragraph:

Abstract of the Disclosure

The present invention relates to a method of screening for compounds that inhibit the virulence of *Pseudomonas* bacteria and comprises the steps of: providing a culture medium comprising *Pseudomonas* bacteria, administering a test compound to said bacteria, and then detecting the presence or absence of inhibition of the catabolite repression control (Crc) protein in the bacteria. The inhibition of the Crc protein indicates that the compound has antivirulence activity against *Pseudomonas* bacteria. Antisense oligonucleotides that inhibit expression of the Crc protein in a *Pseudomonas* bacteria and is nuclease resistant are also disclosed. Antivirulence compounds and the uses thereof in treating *Pseudomonas* infections are also disclosed.

Sub
B2